Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arrowhead Pharmaceuticals stock

Learn how to easily invest in Arrowhead Pharmaceuticals stock.

Arrowhead Pharmaceuticals Inc is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Arrowhead Pharmaceuticals employs 329 staff and has a trailing 12-month revenue of around $249.9 million.

How to buy shares in Arrowhead Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARWR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Arrowhead Pharmaceuticals stock price (NASDAQ: ARWR)

Use our graph to track the performance of ARWR stocks over time.

Arrowhead Pharmaceuticals shares at a glance

Information last updated 2022-09-18.
Latest market close$30.93
52-week range$26.81 - $84.83
50-day moving average $42.03
200-day moving average $45.88
Wall St. target price$74.46
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.08

Buy Arrowhead Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arrowhead Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arrowhead Pharmaceuticals price performance over time

Historical closes compared with the close of $30.93 from 2022-09-23

1 week (2022-09-19) -9.83%
1 month (2022-08-26) -22.79%
3 months (2022-06-24) -10.24%
6 months (2022-03-25) -29.88%
1 year (2021-09-24) -52.68%
2 years (2020-09-25) -31.14%
3 years (2019-09-26) 13.42%
5 years (2017-09-26) 745.08%

Arrowhead Pharmaceuticals financials

Revenue TTM $249.9 million
Gross profit TTM $138.3 million
Return on assets TTM -13.42%
Return on equity TTM -33.79%
Profit margin -61.59%
Book value $4.29
Market capitalisation $3.7 billion

TTM: trailing 12 months

Arrowhead Pharmaceuticals share dividends

We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.

Have Arrowhead Pharmaceuticals's shares ever split?

Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.

Arrowhead Pharmaceuticals share price volatility

Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $26.81 up to $84.83. A popular way to gauge a stock's volatility is its "beta".

ARWR.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 1.4099. This would suggest that Arrowhead Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.

Frequently asked questions

What percentage of Arrowhead Pharmaceuticals is owned by insiders or institutions?
Currently 2.65% of Arrowhead Pharmaceuticals shares are held by insiders and 69.601% by institutions.
How many people work for Arrowhead Pharmaceuticals?
Latest data suggests 329 work at Arrowhead Pharmaceuticals.
When does the fiscal year end for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's fiscal year ends in September.
Where is Arrowhead Pharmaceuticals based?
Arrowhead Pharmaceuticals's address is: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
What is Arrowhead Pharmaceuticals's ISIN number?
Arrowhead Pharmaceuticals's international securities identification number is: US04280A1007
What is Arrowhead Pharmaceuticals's CUSIP number?
Arrowhead Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 042797100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site